ClinicalTrials.Veeva

Menu

Beneficial Effects of Exercise and Healthy Diets on Muscle and Adipose Tissue

U

University of Chile

Status

Terminated

Conditions

Metabolic Syndrome

Treatments

Behavioral: Diet Group
Behavioral: Exercise group
Behavioral: Diet + Exercise
Behavioral: Control period

Study type

Interventional

Funder types

Other

Identifiers

NCT01793896
Fondecyt 1130284
INSTITUTE OF NUTRITION 2013 (Other Identifier)

Details and patient eligibility

About

Both dietary caloric restriction (CR) and physical exercise (PE) exert beneficial effects, which retard or prevent age-related diseases and prolong life span. Subjects with the metabolic syndrome age prematurely, therefore preventive measures should be initiated early. The present study intends to demonstrate that physical exercise and/or Mediterranean diet, in middle aged volunteers with the metabolic syndrome, preserve adequate adipose tissue functionality and retard skeletal muscle aging (assessed by mitochondrial biogenesis and accumulation of ROS), by activating several pathways, homologous to CR. The investigators plan to study this by using two approaches: 1) A cross- sectional model, in which the expression of the mentioned metabolic mediators, indicators of muscle mitochondrial biogenesis and muscle oxidative damage will be compared between men with different body compositions, fat distribution, muscle strength and exercise capacity (VO2max). Also, in these men the investigators will assess the expression of uncoupling protein 1 (UCP1) in subcutaneous white adipose tissue (as a measure of adaptive thermogenesis), and inflammatory markers (Interleukin 1-6, Interleukin 1ß and CCL2 chemokine (C-C motif ligand 2)) in preperitoneal adipose tissue, plus inflammation and adipogenesis potential of their cultured preadipocytes. Moreover, in vitro studies will evaluate the functional effects of exposure of a cell lyne of human adipocyte cells (LS14)to factors secreted by media conditioned by the patients´ adipose tissue explants. 2) A prospective intervention in overweight/moderately obese middle aged volunteers that will be assigned to a weight-maintenance period (as a control group), and then randomly y assigned to a Mediterranean diet, exercise training or diet plus training. Before and after 3 months of intervention the investigators will obtain muscle tissue samples to study the expression of Peroxisome proliferator activated receptor (PPAR) gamma coactivator 1 alpha (PGC1), uncoupling protein 3 (UCP3), AMP activated protein kinase (AMPK), Sirtuin 1 (SIRT-1), mitochondrial DNA and oxidative damage indicators (8-oxo-7,8-dihydro-2-deoxyguanosine (oxodG), carboxymethyllysine (CML and its receptor (RAGE)). In vitro studies will evaluate the effect of circulating factors from the patients (serum) on LS14 inflammatory and adipogenic potential, at baseline and after 3 months of intervention.

Full description

METHODOLOGY:

This study will be composed of 2 parts:

I - CROSS SECTIONAL STUDY The aim of this section is to compare men with different body compositions, fat distribution and exercise capacity with respect to their muscle mitochondrial biogenesis, oxidative damage and energy flux regulator molecules, together with their adipose tissue inflammation, adipokine expression and thermogenic potential.

Inclusion criteria :

male sex age 25 - 50 years BMI from 20 - 35 kg/mt2 indication for surgery of an inguinal hernia

Exclusion criteria:

diabetes mellitus chronic neuromuscular or neurological deficits precluding normal physical activity heavy smoking (> 5 cigarettes per day) alcohol intake > 30 g/day chronic diseases such as cancer, HIV-AIDS, renal, pulmonary, cardiac or hepatic conditions.

Before the operation and after signing a written informed consent, the following assessment will be performed:

Medical history including medication intake and complete physical examination. Dietary recall of habitual intake and calculation of AGEs ingestion. Regular physical activity assessment using the International Physical Activity Questionnaire Anthropometrics (height, weight, waist circumference) Fasting blood sampling for routine determinations (haemoglobin,lipoproteins, creatinine,prothrombin, TSH), AGEs concentrations (CML) free fatty acids, adiponectin and 8- Isoprostanes. Fasting and post glucose serum sampling for glucose and insulin measurements, and calculation of Homeostasis Model Assessment (HOMA-IR) and the Matsuda Index for determination of peripheral insulin sensitivity. Resting and exercise indirect calorimetry for estimation of resting energy expenditure, respiratory quotient and VO2 max. Handgrip and quadriceps muscle strength Dual X-Ray Energy Densitometry (DEXA) for estimation of body composition CT scan of abdominal region at L4 level for measurement of visceral and subcutaneous fat areas and estimation of liver fat infiltration. Ultrasound intensity analysis in thigh ultrasonography indicating muscle fat infiltration. After the initial evaluation, subjects will be classified as with or without the metabolic syndrome, according to the international guidelines guidelines, for further analysis of data.

A few days later, during the surgical procedure, a sample of muscle tissue (approximately 200 mg of internal abdominal oblique) will be obtained for measurement of:

Fiber type Messenger Ribonucleic acid (mRNA) expression of PGC-1-alpha, SIRT-1, UCP-3 and AMPK Mitochondrial density by measurement of mitDNA and Cytochrome C activity Oxidative damage (8-oxodG, CML and RAGE).

During the same operation, 2 samples of adipose tissue will also be obtained, one subcutaneous (at the site of the incision) and the other preperitoneal (at the inguinal sac), for in vitro studies:

UCP1 and inflammatory marker (interleukin 6, 1ß, CCL2) expression in mature adipocytes Inflammatory profile and adipogenic potential (expression of lipoprotein lipase, PPAR gamma and adiponectin) in cultured preadipocytes Adipogenic potential and inflammatory expression profile of LS14 adipose cells exposed to conditioned media from adipose tissue explants.

A small part of these adipose tissue samples will be placed in formaldehyde, fixed and stained with H.E for histologic estimation of adipocyte cell size.

II - INTERVENTION STUDY This section intends to demonstrate the effects of a low-AGEs Mediterranean diet and/or exercise, over skeletal muscle metabolic profile and adipogenic/inflammatory features of adipocytes.

Inclusion criteria:

Overweight or obese men and women Ages 25 - 50 years Interest in losing weight

Exclusion criteria:

weight fluctuations (> 3 k in the last 3 months) diabetes mellitus chronic neuromuscular or neurologic diseases heavy smoking (> 5 cigarettes per day) alcohol intake > 30 g/day chronic diseases such as cancer, HIV, renal, pulmonary, cardiac or hepatic conditions.

Subjects will be invited to participate in a trial using a Mediterranean low-AGEs diet and/or physical exercise during 3 months. After signing a written informed consent,subjects will be allocated to one of these interventions, which will be randomly selected, and the following assessment will be performed, at baseline and after 3 months of intervention:

Medical and medication intake history and complete physical examination. Dietary recall of habitual intake and calculation of AGEs ingestion. Physical activity questionnaire (IPAQ) Anthropometrics (height, weight, waist circumference) Fasting blood sampling for routine determinations (haemoglobin, lipoproteins, creatinine, prothrombin and TSH), AGEs concentrations (CML), free fatty acids, adiponectin, 8-Isoprostanes and serum for in vitro adipose tissue studies (see below). Fasting and post glucose blood sampling for glucose and insulin measurements, and calculation of HOMA-IR and the Matsuda Index for determination of peripheral insulin sensitivity. Dual X-Ray Energy Densitometry (DEXA) for estimation of body composition CT scan of abdominal region at L4 level for measurement of visceral and subcutaneous fat areas and estimation of liver fat infiltration Resting and exercise indirect calorimetry for estimation of resting energy expenditure, respiratory quotient and VO2 max. Handgrip and quadriceps muscle strength Ultrasound intensity analysis in thigh indicating muscle fat infiltration Ultrasound guided quadriceps muscle biopsy to measure mitochondrial density (mitDNA) and expression of PGC-1

Enrollment

83 patients

Sex

All

Ages

25 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

CROSS SECTIONAL: male sex, age 25 -50 years, with BMI ranging from 20 to 35 kg/mt2. INTERVENTION STUDY: Overweight or obese men and women aged 25 - 50 years interested in losing weight,will

Exclusion criteria

CROSS SECTIONAL : diabetes mellitus, chronic neuromuscular or neurological deficits precluding normal physical activity, heavy smoking (> 5 cigarettes per day), alcohol intake > 30 g/day and chronic diseases such as cancer, HIV-AIDS, renal, pulmonary, cardiac or hepatic conditions.

INTERVENTION STUDY: weight fluctuations (> 3 k in the last 3 months), diabetes mellitus, chronic neuromuscular or neurologic diseases, heavy smoking (> 5 cigarettes per day) and alcohol intake > 30 g/day, and chronic diseases such as cancer, HIV, renal, pulmonary, cardiac or hepatic conditions.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

83 participants in 4 patient groups

control period
Sham Comparator group
Description:
control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
Treatment:
Behavioral: Control period
Diet group
Experimental group
Description:
Mediterranean diet prescription during 3 months
Treatment:
Behavioral: Diet Group
Exercise group
Experimental group
Description:
Subjects will be trained 3 times a week during 3 months
Treatment:
Behavioral: Exercise group
Diet + Exercise
Experimental group
Description:
Both a dietary prescription plus exercise training during 3 months
Treatment:
Behavioral: Diet + Exercise

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems